ReviewJCO precision oncology2017
Drug-Related Pneumonitis in the Era of Precision Cancer Therapy.
Review in JCO precision oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 66 citations in OpenAlex.
- Bronchoalveolar lavage fluid in immune checkpoint inhibitor-related pneumonitis: from pathophysiological window to a precision diagnostic tool.Frontiers in immunology · 2026Review
- [Risk Factors, Molecular Mechanisms, and Multimodal Early Warning Strategies for Immune Checkpoint Inhibitor-associated Pneumonitis in Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- State-of-the-Art Imaging in Antibody-Drug Conjugate Treatment for Advanced Bladder Cancer.Korean journal of radiology · 2025Review
- Heterogeneity of Checkpoint Inhibitor-Associated Pneumonitis: A Multicenter Study on Inflammatory Subtypes and Clinical Outcomes.Cancer medicine · 2025Article
- Impact of Huisheng Oral Solution Combined with Immune Checkpoint Inhibitors and Chemotherapy in Patients with Stage III-IV Non-Small Cell Lung Cancer: A Retrospective Analysis.Journal of Cancer · 2025Article
- High-Grade Pneumonitis Events in Patients With Unresectable, Locally Advanced NSCLC Treated With Definitive Chemoradiation Followed by Adjuvant Durvalumab.JTO clinical and research reports · 2024Article
- Updates in Drug-Related Pneumonitis Due to Targeted Oncologic Therapies.Journal of immunotherapy and precision oncology · 2024Review
- The radiologist's role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review.Insights into imaging · 2024Review
- Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung Disease.JTO clinical and research reports · 2024Article
- Adenovirus pneumonia mimicking osimertinib-induced pneumonitis in a patient with advanced NSCLC with EGFR mutation: A case report.Thoracic cancer · 2024Article
- Diffuse Pneumonitis after Lutetium-177-PSMA-617 Treatment in a Patient with Metastatic Castration-Resistant Prostate Cancer.BMJ case reports · 2024Article
- Clinical spectrum of Chinese hospitalized lung cancer patients with concomitant interstitial lung disease: before and after the new era of LC treatment.Clinical and experimental medicine · 2023Article
- Radiation Recall Pneumonitis: The Open Challenge in Differential Diagnosis of Pneumonia Induced by Oncological Treatments.Journal of clinical medicine · 2023Review
- Clinical applications of radiomics in non-small cell lung cancer patients with immune checkpoint inhibitor-related pneumonitis.Frontiers in immunology · 2023Review
- Analysis of 12 cases of antineoplastic agents-induced interstitial lung disease.Frontiers in pharmacology · 2023Article
- Article
- Review
- Demystifying idiopathic interstitial pneumonia: time for more etiology-focused nomenclature in interstitial lung disease.Expert review of respiratory medicine · 2022Review
- Research Progress on Radiotherapy Combined with Immunotherapy for Associated Pneumonitis During Treatment of Non-Small Cell Lung Cancer.Cancer management and research · 2022Review
- Imaging features of toxicities associated with immune checkpoint inhibitors.European journal of radiology open · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Drug-related pneumonitis as a result of novel cancer therapy provides new challenges for providers of cancer care in the era of precision medicine. Awareness of this emerging entity and knowledge of its manifestations and management guidelines are essential for state-of-the-art practice of clinical oncology. Here, we provide a detailed review of drug-related pneumonitis that develops during precision cancer therapies using immune-checkpoint inhibitors and molecular targeting agents, and we summarize the emerging data that have been obtained by recent investigations to provide a state-of-the-art overview for clinicians involved in cancer care. We focus on immune-checkpoint inhibitor-related pneumonitis, which is an immune-related adverse event of growing interest and increasing clinical significance in current oncology practice that has rapidly expanding access to these agents. Clinical characteristics, radiographic spectrum, and risk factors and outcome of pneumonitis are described for each class of agents, and current treatment guidelines and monitoring recommendations are discussed. This review also indicates the area of unmet clinical need and provides direction for future investigations, as well as emphasizing the importance of a multidisciplinary approach to further understand the mechanisms, develop methods for accurate diagnosis, and optimize management guidelines of drug-related pneumonitis in the era of precision oncology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.